Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KITE 363

Next Previous
Drug Profile

KITE 363

Alternative Names: KITE-363

Latest Information Update: 29 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kite Pharma
  • Developer Gilead Sciences; Kite Pharma
  • Class Anti-inflammatories; Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Skin disorder therapies; Urologics
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Autoimmune diseases of the nervous system; B-cell lymphoma; Diffuse scleroderma; Lupus nephritis; Myositis; Rheumatic disorders; Systemic lupus erythematosus
  • Preclinical Diffuse large B cell lymphoma

Most Recent Events

  • 10 Apr 2026 Phase-I clinical trials in Autoimmune diseases of the nervous system (Treatment-experienced) in Australia (IV) (NCT07304154)
  • 10 Apr 2026 Phase-I clinical trials in Autoimmune diseases of the nervous system (Treatment-experienced) in USA (IV) (NCT07304154)
  • 31 Dec 2025 KITE 363 receives Regenerative Medicine Advanced Therapy (RMAT) status for Diffuse large B cell lymphoma (Second-line therapy or greater, Refractory metastatic disease) in USA (Gilead Sciences pipeline, December 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top